The direct oral anticoagulants (DOACs) represent a major advance in oral anticoagulant
therapy and have replaced the vitamin K antagonists as the preferred treatment for many …

Novel oral anticoagulants (NOACs)(rivaroxaban, dabigatran, apixaban) have been
approved by international regulatory agencies to treat atrial fibrillation and venous …

Apixaban is a new oral anticoagulant with a specific inhibitory action on FXa. No information
is available on the reversal of the antihemostatic action of apixaban in experimental or …

Vitamin K-antagonists (VKA) are the most widely used anticoagulant drugs to treat patients
at risk of arterial and venous thrombosis for the past 50 years. Due to unfavorable …

Ischemic stroke represents one of the leading causes of death and disability in both the
United States and abroad, particularly for patients with prior ischemic stroke or transient …

Immunodeficiency disorders and autoimmune diseases are common, but a lack of effective
targeted drugs and the side-effects of existing drugs have stimulated interest in finding …

Taking a historical perspective, we review the discovery, pharmacology, and clinical
evaluation of the old and new anticoagulants that have been approved for clinical use. The …

Matrix metalloproteinase‐13 (MMP‐13) is a uniquely important collagenase that promotes
the irreversible destruction of cartilage collagen in osteoarthritis (OA). Collagenase …

The anticoagulation field is experiencing a renaissance that began with regulatory approval
of the direct thrombin inhibitor dabigatran, a direct oral anticoagulant (DOAC), in 2010. The …

Unfractionated heparin (UFH), the standard anticoagulant for cardiopulmonary bypass
(CPB) surgery, carries a risk of post-operative bleeding and is potentially harmful in patients …